Efruxifermin

DB19012InvestigationalProtein Based Therapies

Efruxifermin is under investigation in clinical trial NCT06215716 (A Study Evaluating Efruxifermin in Subjects With Non-cirrhotic Nonalcoholic Steatohepatitis (Nash)/metabolic Dysfunction-associated Steatohepatitis (MASH) and Fibrosis).

Mechanism: Pharmacologically active on Beta-klotho
Curator reviewed
Also known as: Immunoglobulin g (synthetic human constant domain fc fragment) fusion protein with fibroblast growth factor 21 (98-arginine,171-glycine,180-glutamic acid) (human mutant clone amg876) · Immunoglobulin g1 (human .gamma.1-chain c-region c-terminal fragment) fusion protein with peptide linker (ggggs)3 fusion protein with fibroblast growth factor 21 (98-arginine,171-glycine,180-glutamic acid) (human), dimer
Code names: AKR-001 · AMG-876

Resolves to

Compound

UNIIC1KR8TZ3NECAS2375240-92-7

Targets

Q86Z14KLB

What you can answer from here — as of July 10, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Efruxifermin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account